Compare APPS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPS | CGEM |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2012 | 2020 |
| Metric | APPS | CGEM |
|---|---|---|
| Price | $11.80 | $21.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $6.25 | ★ $30.13 |
| AVG Volume (30 Days) | ★ 2.4M | 722.5K |
| Earning Date | 06-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,569,000.00 | N/A |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $11.34 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.74 | $5.68 |
| 52 Week High | $15.34 | $23.19 |
| Indicator | APPS | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 52.22 |
| Support Level | $8.03 | $11.87 |
| Resistance Level | $11.71 | $23.19 |
| Average True Range (ATR) | 0.63 | 0.87 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 96.00 | 21.52 |
Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.